A recent trial put patients on clozapine and olanzapine on semaglutide for 36 weeks. They lost 19 pounds on average. HbA1c dropped 0.25%. Meanwhile, most PMHNPs are still telling those patients to "try harder with diet and exercise." This Deep Dive unpacks how to actually use GLP-1 receptor agonists for antipsychotic-induced weight gain — when to start, who's a candidate, what to monitor, how to coordinate with primary care for co-prescribing, and the specific patients where the math says don't bother. We also cover the lithium interaction every PMHNP needs to understand before stacking a GLP-1 on top of mood stabilization, plus the insurance angle that's killing access for the patients who need it most. Based on the full guide at psychnpfellowship.com/glp-1-antipsychotic-weight-gain-pmhnp-2026/